ESC 2021 – finerenone’s song gets a little sweeter
Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
ESC 2021 – Jardiance blows Entresto out of the water
A 21% reduction in the risk of cardiovascular death or hospitalisation paves the way for Jardiance's approval in heart failure with preserved ejection fraction.
Novo bets against Crispr for amyloidosis
Novo moves into amyloidosis not long after Intellia made a splash here.
